The invention discloses a composition exhibiting enhanced bioavailability comprising tri-molecular complex of a natural compound or a natural compound containing component, a divalent or tri-valent metal ion and a phospholipid embedded in natural matrix. The composition of the invention further exhibits a sustained release profile for the natural compound or natural compound containing component. The invention further discloses a process for manufacturing the tri-molecular complex containing composition.

Disclosed are means, methods and compositions of matter useful for treatment of lung inflammation associated with viral and bacterial infections, as well as with systemic inflammation, through administration of umbilical cord blood derived plasma-based compositions. In one embodiment the invention teaches administration of umbilical cord blood plasma together with pterostilbene, and/or sulforaphane, and/or thymoquinone, and/or Epigallocatechin gallate (EGCG) and/or n-acetylcysteine in an aerosolized manner to patients suffering from COVID-19 associated pulmonary deficiencies. In another embodiment, umbilical cord blood plasma is administered with immune stimulatory agents in order to concurrently inhibit propagation of viral load in the lung while suppressing pulmonary deficiencies.

Disclosed are means, methods and compositions of matter useful for treatment of lung inflammation associated with viral and bacterial infections, as well as with systemic inflammation, through administration of umbilical cord blood derived plasma-based compositions. In one embodiment the invention teaches administration of umbilical cord blood plasma together with pterostilbene, and/or sulforaphane, and/or thymoquinone, and/or Epigallocatechin gallate (EGCG) and/or n-acetylcysteine in an aerosolized manner to patients suffering from COVID-19 associated pulmonary deficiencies. In another embodiment, umbilical cord blood plasma is administered with immune stimulatory agents in order to concurrently inhibit propagation of viral load in the lung while suppressing pulmonary deficiencies.

Compositions and methods of using them to protect an animal cell or tissue from a microbial pathogen are described. The compositions can include one or more natural oils or extracts comprising a therapeutically active compound to protect the cell or tissue of the animal from the microbial pathogen by direct inactivation of the microbial pathogen or by blocking the microbial pathogen entrance to the animal cell or tissue. Oil macerates that include a therapeutically active compound extracted from plants are also described.

Compositions and methods of using them to protect an animal cell or tissue from a microbial pathogen are described. The compositions can include one or more natural oils or extracts comprising a therapeutically active compound to protect the cell or tissue of the animal from the microbial pathogen by direct inactivation of the microbial pathogen or by blocking the microbial pathogen entrance to the animal cell or tissue. Oil macerates that include a therapeutically active compound extracted from plants are also described.

Various compositions for treating a skin or mucosal membrane infection contain glycerol, at least one surfactant, an alcohol, a terpene or terpenoid compound, and a copper compound. The composition contains substantially no water. The glycerol may be at least 31.5% or between about 30% and 80% by weight of the composition, the at least one surfactant may be between about 1% and 10% by weight of the composition, the alcohol may be between about 10% and 50% or between about 20% and 60% by weight of the composition, the terpene or terpenoid compound may be between about 0.5% and 10% by weight of the composition, and the copper compound may be between about 1% and 10% by weight of the composition.

Various compositions for treating a skin or mucosal membrane infection contain glycerol, at least one surfactant, an alcohol, a terpene or terpenoid compound, and a copper compound. The composition contains substantially no water. The glycerol may be at least 31.5% or between about 30% and 80% by weight of the composition, the at least one surfactant may be between about 1% and 10% by weight of the composition, the alcohol may be between about 10% and 50% or between about 20% and 60% by weight of the composition, the terpene or terpenoid compound may be between about 0.5% and 10% by weight of the composition, and the copper compound may be between about 1% and 10% by weight of the composition.

Various compositions for treating a skin or mucosal membrane infection contain glycerol, at least one surfactant, an alcohol, a terpene or terpenoid compound, and a copper compound. The composition contains substantially no water. The glycerol may be at least 31.5% or between about 30% and 80% by weight of the composition, the at least one surfactant may be between about 1% and 10% by weight of the composition, the alcohol may be between about 10% and 50% or between about 20% and 60% by weight of the composition, the terpene or terpenoid compound may be between about 0.5% and 10% by weight of the composition, and the copper compound may be between about 1% and 10% by weight of the composition.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.